A weak cold and flu season and a cautious American consumer pushed organic growth to 3%, a full percentage point below the floor of what Haleon has promised investors
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.4% to 392.1p on Wednesday after the consumer health group reported full-year organic revenue growth of 3%, missing the 4-6% medium-term range it has set as its benchmark and leaving investors to weigh whether the shortfall reflects bad luck or something more structural.
Two factors drove the underperformance. North America, which generates 35% of revenues, contracted 0.4% organically as inflation-wary consumers traded down or held back on more discretionary purchases, pulling down vitamins and respiratory categories in particular.
A mild winter compounded the problem, stripping an estimated 40 basis points from the full-year number and 150 basis points from the fourth quarter, when Robitussin posted a double-digit decline.
The profit picture was more flattering. Adjusted operating profit rose 10.5% organically to £2.526 billion, margins expanded 160 basis points, and free cash flow reached £1.913 billion, underpinned by a supply chain productivity programme that has already cut SKU counts by 26% and is targeting £800 million in gross savings over five years.
For 2026, Haleon is guiding for organic revenue growth of 3-5% and returning £500 million to shareholders through buybacks. The dividend rises 7.6% to 7.1p.
Chief executive Brian McNamara pointed to 60% of the business gaining or holding market share as evidence the brands remain competitive. Whether the guidance range looks like progress or a downgrade will depend on whether winter is kinder next year.